Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRF231 in Advanced Solid and Hematologic Cancers
NCT03512340Phase 1Completed
- Sponsor
- Surface Oncology
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of urabrelimab in solid tumor and hematologic malignancy (2 arms), sponsored by Surface Oncology. Primary endpoints: Dose-limiting toxicity at 24 months, Non-tolerated Dose at 24 months and 2 more. Started Mar 2018; status: completed.
02
Drugs
urabrelimab
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT03512340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512340.